Ascendis Pharma A/S (NASDAQ:ASND) Given New $315.00 Price Target at UBS Group

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective raised by research analysts at UBS Group from $269.00 to $315.00 in a report issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. UBS Group‘s target price indicates a potential upside of 14.31% from the stock’s current price.

Several other equities analysts have also recently weighed in on ASND. Citigroup dropped their price target on shares of Ascendis Pharma A/S from $360.00 to $330.00 and set a “buy” rating on the stock in a research report on Monday, October 26th. Stifel Nicolaus decreased their price objective on Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating for the company in a report on Monday, August 31st. Wall Street Zen raised Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Sunday, November 8th. HC Wainwright lowered their price objective on Ascendis Pharma A/S from $344.00 to $335.00 and set a “buy” rating for the company in a research note on Friday. Finally, Morgan Stanley dropped their target price on Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating on the stock in a report on Tuesday, September 1st. Nineteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and a consensus target price of $310.57.

Ascendis Pharma A/S Stock Up 3.2%

ASND traded up $8.48 during trading on Friday, hitting $275.56. 177,699 shares of the company’s stock were exchanged, compared to its average volume of 700,609. Ascendis Pharma A/S has a fifty-two week low of $188.08 and a fifty-two week high of $282.15. The stock has a market cap of $17.19 billion, a P/E ratio of 21.33 and a beta of 0.40. The business’s 50 day moving average is $242.58 and its two-hundred day moving average is $239.65. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The business had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. As a group, equities analysts expect that Ascendis Pharma A/S will post 3.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of the business’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the transaction, the senior vice president owned 3,000 shares of the company’s stock, valued at approximately $810,570. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 40.00% of the company’s stock.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several large investors have recently made changes to their positions in ASND. Perceptive Advisors LLC boosted its holdings in shares of Ascendis Pharma A/S by 41.6% in the 1st quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock worth $350,282,000 after buying an additional 450,000 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Ascendis Pharma A/S during the first quarter worth about $26,837,000. Troluce Capital Advisors LLC purchased a new stake in Ascendis Pharma A/S during the first quarter worth about $22,782,000. Sapient Capital LLC purchased a new stake in Ascendis Pharma A/S during the second quarter worth about $24,581,000. Finally, Frazier Life Sciences Management L.P. raised its position in Ascendis Pharma A/S by 68.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company’s stock worth $60,053,000 after acquiring an additional 91,822 shares during the period.

More Ascendis Pharma A/S News

These are some of the ASND news items that stood out recently:

• Positive Sentiment: Q3 results topped estimates. Ascendis reported earnings of $1.94 per share versus a $0.89 consensus and revenue of $418.71 million versus expectations of $409.40 million. Product revenue rose 89% year over year to €366 million, with YORVIPATH the largest contributor. Ascendis Pharma Q3 results
• Positive Sentiment: Regulatory progress could support future growth. European regulators recommended marketing authorization for TransCon CNP; Ascendis expects a European Commission decision in Q4 2026 and plans a first launch in Germany in Q1 2027. Q3 results and pipeline update
• Neutral Sentiment: Employee warrant grants. Ascendis granted 28,030 warrants to employees. The grants may support retention but could modestly dilute existing shareholders. Employee warrant announcement

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.